1 Erratum to: Drugs (2016) 76:1093–1118 DOI 10.1007/s40265-016-0600-5
Page 1093, Key Points box,
The last point, which previously read:
Newer agents are in development but comparative efficacy and safety is as yet unknown.
Should read:
Pimavanserin was approved recently in the USA and newer agents are in development; however, comparative efficacy and safety are as yet unknown.
Page 1107, Table 5, entitled ‘Drugs used to treat PD psychosis’
The dosage for pimavanserin, which previously read:
40 mg/day
Should read:
34 mg/day (equivalent to pimavanserin tartrate 40 mg/day)
The side effects for pimavanserin, which previously read:
Sedation; postural hypotension
Should read:
Oedema; confusional state
Page 1108, Section 4.1.3, paragraph 3
Sentence 5, which previously read:
A phase II study in 46 patients reported good tolerability over 28 days with a small reduction in psychosis versus placebo using SAPS.
Should read:
A phase II study in 59 patients reported good tolerability over 28 days with a small reduction in psychosis versus placebo using SAPS.
Last sentence, which previously read:
Eleven percent of patients in the treatment group withdrew from the trial because of worsening psychotic symptoms.
Should read:
Six patients in the treatment group withdrew from the trial because of worsening psychotic symptoms.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40265-016-0600-5.
Rights and permissions
About this article
Cite this article
Chang, A., Fox, S.H. Erratum to: Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management. Drugs 76, 1319 (2016). https://doi.org/10.1007/s40265-016-0624-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-016-0624-x